EfficacyCV Risk ProtectionEMPA-REG Outcome TrialGuidelinesExpert's video CHAMPS Prescribing Information Previous Next Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease EXPERT'S VIDEO Read more 2:47 Prof. Sarah Jarvis on Early Initiation of Empagliflozin Watch now Opens in new tab Read more 4:03 Prof. Sarah Jarvis on Empagliflozin as CRM Medication Watch now Opens in new tab Read more 1:28 HF Video Prof. Melanie Davies - Jardiance safety for HF patients with T2D Watch now Opens in new tab Read more 4:07 Empagliflozin to Start Treatment Management Watch now Opens in new tab Read more 2:46 What differentiates Empagliflozin from other generic SGLT2is? Watch now Opens in new tab Read more 1:51 HF Video Prof. Roger Chen - Importance of Catching HF patients early in hospital Watch now Opens in new tab Pagination Load More Home Metabolic Empagliflozin Expert's video
Read more 1:28 HF Video Prof. Melanie Davies - Jardiance safety for HF patients with T2D Watch now Opens in new tab
Read more 2:46 What differentiates Empagliflozin from other generic SGLT2is? Watch now Opens in new tab
Read more 1:51 HF Video Prof. Roger Chen - Importance of Catching HF patients early in hospital Watch now Opens in new tab